Jun 02, 2020
RegeneRx Advisory on ARISE-3 Dry Eye Trial
May 27, 2020
RegeneRx Advisory on Reclassification of Thymosin Beta 4 from Drug to Biologic
May 14, 2020
RegeneRx Joint Venture Announces Efficacy Results of Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259
Apr 20, 2020
RegeneRx Issues Advisory on ARISE-3 Dry Eye Trial
Mar 18, 2020
RegeneRx Issues Advisory on Dry Eye Trial Amid COVID-19 Virus
Feb 13, 2020
RegeneRx Partner Receives Canadian Patent For Treatment of Peripheral Neuropathy
Feb 03, 2020
RegeneRx Partner Updates on Phase 3 Dry Eye Trial
Jan 22, 2020
RegeneRx Publishes Annual Letter to Shareholders
Nov 18, 2019
RegeneRx's Tb4 Significantly Reduces Damage in Ischemic Acute Kidney Injury Model
Oct 16, 2019
RegeneRx JV Partner Updates on Strategic Dry Eye Discussions
Sep 30, 2019
RegeneRx Partner Updates on ARISE-3 Clinical Trial
Sep 10, 2019
RegeneRx to Present at Fall Investor Summit on September 17
Sep 04, 2019
RegeneRx Modifies September Conference Schedule
Jul 29, 2019
RegeneRx's RGN-137 for Epidermolysis Bullosa Subject of New Article in Seeking Alpha Investor Site
Jul 16, 2019
RegeneRx to Present at the Rodman & Renshaw and the Fall Investor Summit Conferences in September 2019
May 28, 2019
RegeneRx Receives Final Payment from Convertible Debt Financing
May 13, 2019
First Patient Enrolled in RegeneRx JV Phase 3 Dry Eye Trial
Apr 22, 2019
RegeneRx Publishes Annual Letter to Shareholders
Mar 27, 2019
RegeneRx to Present at 2019 Spring Investor Summit
Mar 26, 2019
RegeneRx and Lee's Pharm to Accelerate RGN-259 Development in China